Digipath
Home > Boards > Canadian > Biotechs >

Breathtec Biomedical Inc. (BTHCF)

BTHCF RSS Feed
Add BTHCF Price Alert      Hide Sticky   Hide Intro
Moderator: shell3, smoki
Search This Board: 
Last Post: 1/15/2019 6:05:14 PM - Followers: 98 - Board type: Free - Posts Today: 0


 
The Future of Disease Detection 

TOTAL AUTHORIZED SHARES: 100,000,000

NUMBER OF OUTSTANDING LISTED SHARES: 57,364,023

WARRANTS ISSUED BUT NOT EXERCISED: 12,011,665

OPTIONS ISSUED BUT NOT EXERCISED: 2,970,000 

FULLY DILUTED SHARES IF ALL WARRANTS & OPTIONS EXERCISED: 72,345,688 


CSE: BTH  XFRA: BTI  OTC: BTHCF    

 
Company Overview
 

Breathtec’s mission is to develop technologies that use biomarkers in the breath to screen for early signs of diseases such as lung & breast cancers, infectious diseases, diabetes, liver disease, and more. We are focused on developing a low-cost, non-invasive, portable hand-held device to be used by clinician’s in the office, clinic or hospital setting, or by agents screening for infectious diseases at national border entry points (ie: airports).

Field Asymmetric Ion-Mobility Spectrometry (FAIMS) is a highly sensitive chemical analysis method previously used for explosives detection that we have readapted for breath analysis for early disease detection.  FAIMS analysis has been successfully used to identify numerous biomarkers associated with disease but previous approaches have had limited clinical use due to a lack of the reproducibility and sensitivity required, as well as the size and expense of the final device. Breathtec’s goal is to leverage our deep understanding of the FAIMS technology in order to develop an effective and affordable medical screening device.

Regular screening using a simple breath test, could lead to significant advancements in remedial treatment protocols targeting major improvements in survivability and life quality.

 

 
Learn More ›


 
Technology Overview


Breathtec Biomedical Inc. (“Breathtec”) aims to propel development and commercialization of breath analysis screening technologies.

Breathtec holds a license to key University of Florida patent U.S. 8,237,118 entitled “Partial Ovoidal FAIMS Electrode.”

FAIMS is a mass spectrometry technique that exploits differences in ion mobility at very high electric fields, to separate ions in the millisecond timescale after liquid chromatography separation and prior to introduction to a mass spectrometer.

FAIMS technology allows for miniaturization of breath testing devices and will enable development of non-invasive clinical screening.

Eventual commercialization of FAIMS could revolutionize early detection of many deadly diseases.

The Company is actively pursuing multiple, alternative research efforts into FAIMS technology.

“Every individual has a breath print that differentiates them from other people, depending on what’s going on in their body, and that print can tell us a lot about a person, what they’ve been exposed to and what disease they have. That’s what makes the new field of breath testing so promising, because it is non-intrusive, so there is no risk involved, and you can do it anywhere, in a clinic, in a hospital, anywhere.”

Dr. Raed Dweik, Respiratory Institute at Cleveland Clinic 


Learn More >


 
In The Media 

 
Breathtec Biomedical Set to Blaze Trails in MedTech with Breath Analysis

Bill Gates made the news this week with comments that warned of a rapid epidemic. At the Munich Security Conference in Germany, Gates said, “Whether it occurs by a quirk of nature or at the hand of a terrorist, epidemiologists say a fast-moving airborne pathogen could kill more than 30 million people in less than a year. And they say there is a reasonable probability the world will experience such an outbreak in the next 10 to 15 years.”

While Gates comments focused on the progress in vaccine supply chains, the underlying idea of his words are that the world needs a wake-up call about disease prevention. However, there have been important discoveries in modern science and medical equipment that are transforming the space.

It is actually the rise of early-detection diagnostic devices that might have the biggest impact on saving lives in the future. Advancements that allow physicians to efficiently assess a patient’s medical condition are invaluable not only in the time of a crisis but in the day-to-day healthcare market. Breathtec Biomedical Inc. (BTH:CSE) (BTHCF) is a leading innovator in this space.

Breathtec today provided a corporate update of significant developments and the outlook for near-term opportunity. The company’s diagnostic portfolio includes its proprietary FAIMs technology and the NaNose technology.


Breathtec is Improving Upon Its Innovative Design

Breathtec has completed testing on the V2 prototype for its flagship FAIMS technology. The new design is sleeker and its non-radioactive ionization source and a new square wave generation system remain efficient and agile. The company will patent the new design features specifically the improvement to miniaturized FAIMS cells and the miniaturization of all high-voltage and low-voltage electronic components. The Company will now begin the performance testing phase of this new V2 prototype to continue to characterize the analytical performance of the system in preparation for a pilot clinical study in the fall of 2017. The company has established a clear path to market and will be scheduling a pre-submission meeting with the FDA in the coming months to receive a complete understanding of the regulatory and clinical testing requirements to commercialize the technology.

In addition, Breathtec has expanded its team and brought on experienced consultants to develop a Quality System and Design Control process and finish the creation of these tech platforms.

“We have the right technology and the right team to get to market and will be working diligently to accomplish this in an efficient and time sensitive manner,” Breathtec CEO Guy LaTorre stated. “Our goals are ambitious and challenging but we feel confident that, with your support, we will be able to make significant contributions to the field of breath analysis, which will be worthwhile for the patient, medical community and for our investors.” 


Paradigm Shift: Breathtec’s Early Screening Technology

Based in Florida, Breathtec’s aim is to battle disease through prevention and one’s own breath. Na-Nose, an advanced stage breath analysis, can detect a variety of diseases, including, among others, streptococcus; hemophilus influenza, chickenpox; and the common cold. “Na-Nose was developed using space-age nanotechnology to be extremely sensitive for the detection of multiple trace chemicals or volatile organic compounds in the breath,” stated Dr. Raj Attariwala, lead engineer of Breathtec. “It uses machine learning to effectively sniff our unique patterns of disease processes in the body.”

Technology with the power to recognize diseases that are not even yet showing physical symptoms would be the answered prayer of patients and physicians everywhere. NaNose represents the possibility of a paradigm shift in point-of-care technology and overall quality of life.

The Point-of-Care Diagnosis market is rising and, according to MarketandMarkets.com, is expected to reach $36.96 billion by 2021. Breathtec stands on the precipice of a market that is rising with transformative technology in hand. Investors should continue to watch this company that has serious potential to benefit patient and healthcare providers.

Learn More>


Leadership @ Breathtec Biomedical Inc

headshot_chrisMoreau
Christopher J. Moreau, Chief Executive Officer

Mr. Moreau is a seasoned business professional in the life sciences sector with a strong background in medical devices and biomarker research. Mr. Moreau is currently the CEO of Nash Pharmaceuticals Inc., a privately-held drug development company and was previously President & CEO of Miraculins Inc, a public company where he raised in excess of C$13 million to fund research & development for screening tests for prostate cancer, skin cholesterol and type 2 diabetes.



Michael T. Costanzo, Ph.D., Chief Technical Officer

Dr. Costanzo enjoys a passion for science that has directed his career path firmly into the field of analytical chemistry. Over the past five years he has investigated a variety of advanced experimental methodologies and instrumentation with the Yost Research Group at the University of Florida. During this period he utilized UV spectroscopy to help in standardizing procedures for manufacturing respiratory medications, employed novel ion mobility spectrometric techniques and devices to analyze exhaled breath, and performed multiple metabolomics studies of melanoma. Through his efforts, he acquired a vast knowledge of analytical techniques and methodologies and an immense desire for scientific progress.

Previously, Costanzo obtained his Bachelor of Science in chemistry at the State University of New York (Buffalo). During this period he conducted research under Dr. Troy Wood utilizing mass spectrometry to examine products of enzymatic protein digestion in the interest of studying metabolic markers of autism in children. Upon graduation in 2010 he moved to the University of Florida for Ph.D. studies and as a result of his efforts has recently joined with Breathtec Biomedical to propel his own bioanalytical research through the development of revolutionary clinical devices utilizing his background in ion mobility, mass spectrometry, and exhaled breath analysis.
 


Raj Attariwala, MD, PhD., Lead Engineer

Dr. Attariwala is a dual board certified Radiologist and Nuclear Medicine physician certified in both Canada and the United States. He received his formal medical training at University of British Columbia with periods of specialized medical training at Memorial Sloan Kettering Cancer Centre (New York), UCLA and USC. He holds a doctorate in Biomedical Engineering from Northwestern University (Evanston, IL).

Dr. Attariwala is a practicing physician in British Columbia and owner of AIM medical imaging. He has pioneered advances in the field of whole body medical imaging and authored numerous publications and presented at international medical conferences on whole body imaging and cancer detection.

Dr. Attariwala has extensively investigated breath testing applications and efficacy in a related role at Cannabix Technologies Inc. where he developed a breath testing system for drug impairment.


Image result for richard yost
Richard A. Yost Ph.D., Scientific Advisor

Dr. Yost, Col. Allen R. & Margaret G. Crow Professor and Head of Analytical Chemistry at the University of Florida received his B.S. degree in Chemistry from the University of Arizona in 1974. In 1975 he pursued an NSF graduate fellowship at Michigan State University focusing on electronics and computerized instrumentation. He received his Ph.D. in 1979 and assumed the position of Assistant Professor at the University of Florida and went on to become head of the Analytical Chemistry Division.

Dr. Yost’s research has involved over 100 graduate students funded by over $40 million in research grants, and has published over 160 papers and 16 patents. Over $30 billion worth of instruments have been sold based on these patents.

He serves as a member of the Florida Board of Governors (Regents) and as the Chair of the Advisory Council of Faculty Senates of Florida. He is past Chair of the UF Faculty Senate and served on the UF Board of Trustees. He served as Treasurer and Secretary of the American Society for Mass Spectrometry, and on the editorial boards of The Journal of the American Society for Mass Spectrometry and The International Journal of Mass Spectrometry.

Yost Research Group


- Corporate Links -

Digipath
BTHCF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BTHCF News: Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn's Disease 12/03/2018 09:45:25 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#4327  Sticky Note Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Diogenes of Sinope 11/01/18 09:04:07 AM
#2063  Sticky Note Commercial Adoption of Ion Mobility Technology Drives Multi-Omics Application shell3 07/23/17 11:38:00 AM
#4562   Built In Partnership Potential - Re: Additional Lead Targets AMG 01/15/19 01:49:22 AM
#4561   CASH for NASH!!! WOOHOO!!! :)))$$$ smoki 01/14/19 11:43:45 PM
#4560   Like it! smoki 01/14/19 12:44:04 PM
#4559   Hoping for more, bought in this way too high. ds634843 01/14/19 12:28:20 PM
#4558   News UCParadise 01/14/19 08:28:59 AM
#4556   Re: Lead Compound NP-160 (NASH) & Lead Compound AMG 01/13/19 02:39:31 PM
#4555   Built in Partnership Potential - Re: Lead Compound AMG 01/13/19 02:13:38 PM
#4554   Built in Partnership Potential - Re: Lead Compound AMG 01/13/19 02:01:41 PM
#4553   Welp...that didn't take long. AMG 01/13/19 09:58:48 AM
#4552   a rational person would think to know my namah sivaya 01/13/19 09:48:53 AM
#4551   It would be nice if that was Thee AMG 01/13/19 09:12:29 AM
#4550   i was in it from .10 several years namah sivaya 01/13/19 09:08:58 AM
#4549   O salutations to the auspicious one! AMG 01/13/19 08:10:38 AM
#4548   like they say, namah sivaya 01/13/19 07:57:58 AM
#4547   I hear ya Shell...however there is already a AMG 01/12/19 11:14:40 AM
#4546   Good stuff...if I had to bet the farm...I'd AMG 01/12/19 10:49:43 AM
#4545   I figured slightly higher but agree at these RolandDoe 01/12/19 10:43:44 AM
#4544   Just to clarify my reason for taking a shell3 01/12/19 10:17:16 AM
#4543   Good Stuff...All Things Breathtec Crash Course AMG 01/12/19 09:24:46 AM
#4542   I don’t know but good question shell3 01/12/19 09:21:05 AM
#4541   Correction: If Btec sold FAIMS for 300M USD, AMG 01/12/19 09:04:58 AM
#4540   Yo Shell! AMG 01/12/19 08:45:50 AM
#4535   Follow up Part II: Just know the type AMG 01/11/19 01:58:09 AM
#4534   Follow up: Speaking of Dr. Frost (Yost). It AMG 01/11/19 12:57:54 AM
#4533   I have never implied I do not own AMG 01/11/19 12:12:24 AM
#4532   I invested because of the FAIMS tech uses tcm7 01/10/19 06:48:53 PM
#4531   I have no idea how you read all AMG 01/10/19 02:57:51 PM
#4530   So we are F’d then!! smoki 01/10/19 02:30:10 PM
#4529   When you say "we" have to be happy AMG 01/10/19 12:59:37 PM
#4528   I had thought that Bth/Nash would incorporate the tcm7 01/10/19 12:53:37 PM
#4527   I think the sell off of FAIMS is AMG 01/10/19 11:26:45 AM
#4526   Should have not been a Reverse Split without shell3 01/10/19 10:57:57 AM
#4525   Agreed it's Greed (Dante's Inferno - 4th Circle AMG 01/10/19 10:56:40 AM
#4524   Press Release shell3 01/10/19 09:10:35 AM
#4523   January 2019 Monthly Report: Number of Outstanding AMG 01/08/19 11:37:59 PM
#4522   The Numerof 2019 Global Medical Device Outlook AMG 01/08/19 09:51:01 AM
#4521   The Numerof 2019 Global Pharma Outlook AMG 01/08/19 09:50:53 AM
#4520   OAN: Deal-making in the global health-care sector is AMG 01/08/19 09:50:41 AM
#4519   ...May God Help Us All. We can only AMG 01/08/19 08:15:26 AM
#4518   You need .40's to break even. Other's need AMG 01/08/19 07:50:04 AM
#4517   My 1st investment in Bth $ 7,000 smoki 01/07/19 07:49:48 PM
#4516   Let everyone know when you're ready to dump AMG 01/05/19 09:22:59 PM
#4515   Zero Volume? dilligence 01/05/19 08:28:50 PM
#4514   The CSE and TD Ameritrade are both reporting AMG 01/04/19 09:59:44 AM
#4513   Back@cha Buddy. /////AMG AMG 01/03/19 06:39:41 PM
#4512   Can’t disagree with that! Happy new year. RolandDoe 01/03/19 05:21:42 PM
#4511   It means no one but autobots and idiots AMG 01/03/19 02:46:31 PM
#4510   4C/dilligence - There isn't any competition between Breathtec AMG 01/03/19 02:39:22 PM
#4509   Definitely would like to see more than $1100 RolandDoe 01/03/19 02:38:11 PM
#4508   Word is gettin out ... I Heart you smoki 01/03/19 02:15:09 PM
PostSubject